Cargando…

Characteristics of Tedizolid Non-susceptible Enterococcal Clinical Isolates

BACKGROUND: Tedizolid is a novel oxazolidinone antibiotic with activity across a broad range of gram-positive pathogens. The aim of this study was to describe the characteristics of tedizolid (TZD) resistant enterococcal clinical isolates. METHODS: Tedizolid resistant isolates were recovered from pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dhand, Abhay, Lee, Leslie, Lobo, Stephen, Wang, Guiqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631414/ http://dx.doi.org/10.1093/ofid/ofx163.1720

Ejemplares similares

1798. Phenotypic and Genotypic Impact of Antibiotic Stewardship Intervention on Daptomycin-Nonsusceptible Enterococcus faecium (DNSE) Clinical Isolates
por: Dhand, Abhay, et al.
Publicado: (2018)

2171. Clinical Characteristics and Outcomes of Immunocompromised Patients with Enterococcal Pneumonia
por: Ajaka, Leama, et al.
Publicado: (2022)

Comparative Efficacies of Linezolid vs. Tedizolid in an Experimental Murine Model of Vancomycin-Resistant Enterococcal (VRE) Bacteremia
por: Abdelhady, Wessam, et al.
Publicado: (2019)

In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
por: Zhang, Huiyun, et al.
Publicado: (2022)

2224. Aminopenicillins versus Non-aminopenicillins for Treatment of Enterococcal Cystitis
por: de Oca, Jamison Montes, et al.
Publicado: (2022)

2428. Lower Rates of Antibiotic Treatment of Vancomycin-Resistant Compared With Vancomycin Susceptible Enterococcal Bacteriuria
por: Vendittelli, Bridget, et al.
Publicado: (2018)

1521. Non-faecium Non-faecalis enterococcal bloodstream infections in patients with cancer
por: Axell-House, Dierdre B, et al.
Publicado: (2022)

622. The Accessory Genome in Enterococcal Bacteremia: Results from the Vancomycin-Resistant Enterococcal Bacteremia Outcomes Study (VENOUS)
por: Simar, Shelby, et al.
Publicado: (2019)

Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates (‘the MIC Creep’): implications for therapy
por: Dhand, Abhay, et al.
Publicado: (2012)

264 Results of the Surveillance of Tedizolid Activity and Resistance (STAR) Program: In Vitro Susceptibility of Gram-Positive Clinical Isolates Collected in 2013 From the United States
por: Bien, Paul, et al.
Publicado: (2014)

1578. Rifampicin Reduces Tedizolid Concentrations When Co-Administered in Healthy Volunteers
por: Lee, Lawrence, et al.
Publicado: (2019)

Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Nosocomial- and Community-Acquired Infections in United States Hospitals (2014–2016)
por: Mendes, Rodrigo E, et al.
Publicado: (2017)

306. Safety and Tolerability of Tedizolid as Oral Treatment for Bone and Joint Infections
por: Launer, Bryn, et al.
Publicado: (2018)

1289. Assessing the Safety and Efficacy with Prolonged Use of Tedizolid in Orthopedic Patients
por: Garza, Daniel E, et al.
Publicado: (2023)

1814. External Validation of Precision Antibiotic Therapy for Enterococcal Bloodstream Infections
por: Lee, Tiffany, et al.
Publicado: (2018)

123. Impact of Enterococcal Bacteremia on Clinical Outcomes in Patients with Liver Cirrhosis
por: Phe, Kady, et al.
Publicado: (2019)

2421. Tedizolid Is Well-Tolerated Among Patients Receiving Prolonged Treatment Courses
por: Marini, Rachel V, et al.
Publicado: (2018)

Antimicrobial Susceptibility of Enterococcal Species Isolated from Antibiotic-Treated Dogs and Cats
por: KATAOKA, Yasushi, et al.
Publicado: (2014)

712. Identification of a Novel Tedizolid Resistance Mutation in rpoB of Methicillin-Resistant Staphylococcus aureus
por: Werth, Brian, et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Clinical characteristics and outcome of patients with enterococcal liver abscess
por: Große, K., et al.
Publicado: (2021)

Infectious Disease Consultation Is Associated with Decreased Mortality with Enterococcal Bloodstream Infections
por: Lee, Rachael A, et al.
Publicado: (2017)

1085. Enterococcal Cardiac Implantable Electronic Device (CIED) Infections: Clinical Features and Outcomes
por: Oh, Timothy S, et al.
Publicado: (2018)

Clinical Characteristics And Risk Factors In Mixed-Enterococcal Bloodstream Infections
por: Zheng, Cheng, et al.
Publicado: (2019)

Tedizolid: new data and experiences for clinical practice
por: Lletí, Miguel Salavert, et al.
Publicado: (2021)

2287. Real-world Use of Tedizolid Phosphate: A Case Series of Long-Term Tolerability
por: Morrisette, Taylor, et al.
Publicado: (2019)

1083. Clinical Efficacy of Tedizolid for the Treatment of Mycobacterium abscessus complex Infections in Solid Organ Transplant Recipients
por: Poon, Yi Kee, et al.
Publicado: (2020)

1832. Rise in Deaths from Firearm Injury and Drug Overdose During COVID-19 Pandemic and its Impact on Organ Donation in the United States
por: Dhand, Roshan, et al.
Publicado: (2023)

333. Tedizolid Activity against Gram-Positive Bacterial Isolates Causing Bone and Joint Infections in the United States (2015–2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

Tedizolid Activity Against Clinical Mycobacterium abscessus Complex Isolates—An in vitro Characterization Study
por: Tang, Ying Wei, et al.
Publicado: (2018)

1248. Genomic Sequencing and Clinical Data Integration for Next-Generation Infection Prevention
por: Chen, Donald, et al.
Publicado: (2018)

1009. Venous 1: A Prospective Multicenter Cohort Study of Enterococcal Bacteremia
por: Contreras, German, et al.
Publicado: (2018)

1017. Impact of Enterococcal Bloodstream Infection on Mortality in Patients With Acute Myelogenous Leukemia
por: Messina, Julia, et al.
Publicado: (2018)

2110. Enhancing Antibiotic Efficacy Against Enterococcal faecium with Bacteriophage and Antimicrobial Peptides
por: Bleick, Callan, et al.
Publicado: (2023)

Broad In Vitro Activity Analysis of Tedizolid Compared with Other Agents against a Global Collection of Gram-Positive Isolates Causing Bloodstream Infections (2014–2016)
por: Mendes, Rodrigo E, et al.
Publicado: (2017)

1643. Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI)
por: Avery, Lindsay, et al.
Publicado: (2018)

Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?
por: Ruth, Mike Marvin, et al.
Publicado: (2020)

Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection
por: Shaw, Timothy David, et al.
Publicado: (2021)

Retrospective Study of Linezolid vs. Daptomycin for the Treatment of Vancomycin--resistant Enterococcal Bloodstream Infection
por: Rai, Rena, et al.
Publicado: (2017)

In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid
por: Vanegas Múnera, Johanna Marcela, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5ibeamc1v7uv1re70fap4vhn0i